Exelixis Inc. (EXEL) News Nov 20, 2014, 5:14 p.m.

Exelixis Inc. (EXEL) News Nov 20, 2014, 5:14 p.m.
MarketWatch News on EXEL
Apple, Tesla hit intraday records; Possible breach at Home Depot 2:15 p.m. Sept. 2, 2014 - Angela Johnson
Exelixis shares plunge 55% after disappointing trial results 8:40 a.m. Sept. 2, 2014 - Tomi Kilgore
Biotechs still sliding, but Wall Street says don't hit panic button just yet 1:43 p.m. March 26, 2014 - Russ Britt
HMA’s pre-emptive strike against ‘60 Minutes’ 4:44 p.m. Nov. 30, 2012 - Russ Britt
Chipotle vs. Taco Bell: testing Einhorn's thesis 5:37 a.m. Oct. 4, 2012 - The Trading Deck
Exelixis prices stock offering at 0.7% discount 11:21 a.m. Aug. 9, 2012 - MarketWatch.com
Exelixis slides 12% on stock, debt offering 2:39 p.m. Aug. 6, 2012 - Val Brickates Kennedy
FDA to speed Exelixis thyroid-cancer-drug review 5:35 a.m. July 30, 2012 - MarketWatch.com
Stocks to watch Thursday: GM, Agilent, NetApp 6:51 a.m. Feb. 16, 2012 - MarketWatch
Exelixis licenses cancer-drug R&D to Merck & Co. 7:26 a.m. Dec. 21, 2011 - MarketWatch.com
Loathe that investment theme? Perfect! 12:03 p.m. Nov. 8, 2011 - The Trading Deck
Exelixis plunges on drug study woes 11:05 a.m. Nov. 1, 2011 - Val Brickates Kennedy
Stocks to watch Tuesday: Exelixis, DirecTV, Leap 5:46 a.m. Nov. 1, 2011 - MarketWatch
Exelixis slides, Allstate up in after-hours trade 5:48 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis shares fall without FDA study commentary 5:05 p.m. Oct. 31, 2011 - Wallace Witkowski
Exelixis shares resume trading, drop 35% 4:44 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis rallies 21% on drug study 10:46 a.m. Oct. 24, 2011 - Val Brickates Kennedy
Icahn reports new stakes in Vector Group, El Paso 6:52 p.m. Aug. 15, 2011 - MarketWatch.com
ASCO studies shake up drug stocks 3:17 p.m. June 7, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 5:50 p.m. June 6, 2011 - Kate Gibson


Other News on EXEL
Exelixis: Why This Company Could Become The Next Dendreon 12:54 p.m. Nov. 18, 2014 - Seeking Alpha
Update: Exelixis Announces Very Positive Phase 1 Trial Data 1:28 a.m. Nov. 18, 2014 - Seeking Alpha
Biotech Weekly: Here Come The Institutional Holdings Updates 8:31 a.m. Nov. 17, 2014 - Seeking Alpha
Update: Exelixis Reports Q3 Earnings - Impact To My Thesis 4:42 a.m. Nov. 7, 2014 - Seeking Alpha
Exelixis completes enrollment in cabozantinib Phase 3 7:31 a.m. Nov. 6, 2014 - Seeking Alpha
Exelixis' (EXEL) CEO Mike Morrissey on Q3 2014 Results - Earnings Call Transcript 10:42 p.m. Nov. 4, 2014 - Seeking Alpha
Exelixis (EXEL) Q3 2014 Results - Earnings Call Webcast 4:55 p.m. Nov. 4, 2014 - Seeking Alpha
10-Q: EXELIXIS, INC. 4:05 p.m. Nov. 4, 2014 - Edgar Online - (EDG = 10Q, 10K)
Notable earnings after Tuesday's close 5:35 p.m. Nov. 3, 2014 - Seeking Alpha
Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog 2:35 p.m. Nov. 3, 2014 - Zacks.com
Ad Comm smacks down Sonacare's HIFU device for prostate cancer 1:53 p.m. Oct. 3, 2014 - Seeking Alpha
Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog 9:50 a.m. Oct. 3, 2014 - Zacks.com
Exelixis (EXEL) Is in Oversold Territory: What's Next? - Tale of the Tape 9:41 a.m. Oct. 3, 2014 - Zacks.com
Update: Exelixis Announces Very Positive Results From The CoBRIM Trial - Impacts To My Bull Thesis 9:57 a.m. Sept. 29, 2014 - Seeking Alpha
Exelixis up on clinical trial results 7:38 a.m. Sept. 29, 2014 - Seeking Alpha
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. 7:41 p.m. Sept. 28, 2014 - GuruFocus.com
Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape 8:53 a.m. Sept. 18, 2014 - Zacks.com
Anika Therapeutics: A Recent Greenblatt Small Cap Biotech Pick 8:38 a.m. Sept. 16, 2014 - Seeking Alpha
Tokai Pharmaceuticals IPO: Lack Of Product Diversity Should Leave Investors Cautious 8:41 a.m. Sept. 15, 2014 - Seeking Alpha
Exelixis' (EXEL) CEO Michael Morrissey Presents at Morgan Stanley Healthcare Conference (Transcript) 6:04 p.m. Sept. 9, 2014 - Seeking Alpha

Press Releases on EXEL
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 9:00 a.m. Nov. 18, 2014 - PR Newswire - PRF
Exelixis Announces PositivePreliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib 4:20 a.m. Nov. 16, 2014 - BusinessWire - BZX
Exelixis to Present at theStifel2014Healthcare Conference on Tuesday, November 18 4:40 p.m. Nov. 11, 2014 - BusinessWire - BZX
Exelixis CompletesEnrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma 6:04 a.m. Nov. 6, 2014 - BusinessWire - BZX
Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer 4:14 p.m. Nov. 4, 2014 - BusinessWire - BZX
Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update 4:13 p.m. Nov. 4, 2014 - BusinessWire - BZX
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma 8:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014 3:12 p.m. Oct. 14, 2014 - BusinessWire - BZX
Exelixis Announces Positive Results from Phase 3 Pivotal Trial ofCobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma 2:00 a.m. Sept. 29, 2014 - BusinessWire - BZX
Exelixis Announces Cobimetinib Phase3coBRIM Results toBePresented at ESMO 2014 Congress 12:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 7:40 a.m. Sept. 12, 2014 - PR Newswire - PRF
Exelixis to Present at theMorgan Stanley Global Healthcare Conference on Tuesday, September 9 3:05 p.m. Sept. 8, 2014 - BusinessWire - BZX
Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trialof Cabozantinib in Men with MetastaticCastration-ResistantProstate Cancer 5:00 p.m. Sept. 1, 2014 - BusinessWire - BZX
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 7:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Exelixis Announces Second Quarter 2014 Financial Results 3:14 p.m. July 31, 2014 - BusinessWire - BZX
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 8:20 a.m. July 31, 2014 - PR Newswire - PRF
Biotech Companies Release Quarterly Financials and Announce Earnings Release Dates - Research Reports on Illumina, Alexion, Questcor, Jazz Pharmaceuticals and Exelixis 7:40 a.m. July 29, 2014 - PR Newswire - PRF
SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead 7:40 a.m. July 18, 2014 - PR Newswire - PRF
Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc. 2:05 p.m. July 17, 2014 - PR Newswire - PRF
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 3:06 p.m. July 16, 2014 - BusinessWire - BZX